NCT05623540

Bisphosphonates Use After Total Joint Arthroplasty

Postoperative Use of Bisphosphonates Reduces Adverse Outcome After Primary Total Joint Arthroplasty: A Nationwide Population-based Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 27,405 (actual)
• Sponsor: National Defense Medical Center, Taiwan · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: —

Summary

Background Bisphosphonates has been associated with a decreased risk of revision total joint replacements because of its effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent and the influence of bisphosphonates on associated complications and subsequent total joint arthroplasty (TJA) remains unknown. This study is to investigate the association between the use of bisphosphonates and risk of adverse outcomes after primary TJA. Materials and Methods This matched cohort study utilized National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000- December 2015 inclusive). Study participants were further categorized into two groups: bisphosphonates users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHR) of revision surgery, adverse outcomes of primary surgery and undergoing subsequent TJA were calculated using Cox regression analysis.

Conditions

• Diphosphonates

Interventions

Type	Name	Description
DRUG	Bisphosphonates, Combinations

Timeline

• Start date: 2000-01-01
• Primary completion: 2015-12-31
• Completion: 2022-11-02
• First posted: 2022-11-21
• Last updated: 2022-11-22

Locations

1 site across 1 country: Taiwan